pharm edaily

[Shin-Min Joon, Edaily Reporter] Huons Global reported on May 15 its consolidated financial results for this year‘s January March period.

Huons Global CI. (Image=Huons Global)

The company reported 199.1 billion won in consolidated sales, 25.6 billion won in operating profit, and 26.1 billion won in net profit, reflecting year on year changes of -1.4%, -1.5%, and +13.1%, respectively.

Huons Global said that consolidated revenue for the first quarter fell compared to the same period last year, but with improved performances in the group’s core businesses: growth in ethical drug (ETC) business for Huons and strong aesthetic exports for Humedix.

The group improved management efficiency and reduced selling, general, and administrative (SG&A) expenses, while increased R&D investments for future growth, resulting the operating profit for the first quarter to fall year over year.

The Huons Group said that R&D investment for the first quarter rose 34% to 17.8 billion won from 13.3 billion won in the same period last year. The group attributed the increase in R&D spending to efforts to secure key new drug candidates (pipelines) and its clinical trial costs for Huons and Huonslab.

Huons (CEO Song Soo young) reported consolidated sales of 145.8 billion won, operating profit of 12.8 billion won, and net profit of 12.3 billion won, reflecting year-on-year changes of -1.3%, +20.1%, and +26%, respectively.

Huons’ ETC business showed improved performance driven by continued growth in chronic disease drugs and increased exports of injections to the U.S. and eye drops to the rest of the world.

On May 2 Huons received two U.S. Food and Drug Administration’s (FDA) Abbreviated New Drug Application (ANDA) approvals, the two additions to its five FDA approvals for injections. This accelerates Huons’ exports expansion efforts to North America. The company continued stable performance in CMO business, powered by increased operation rate of the eye drop line at the second production facility.

Huons significantly improved its profitability as a result of improved performance of its subsidiaries and cost management efforts. Huons reported consolidated operating profit margin of 8.8%, separate operating profit margin of 9.8%. This marks the highest quarterly operating profit margin since 2024.

Huons N, a spin off of Huons’ health functional food business newly-launched on May 2, turned in profit in the first quarter with sales of 11.7 billion won and operating profit of 200 million won. HuonsLifeSciences drastically reduced the deficit, reporting its first quarter sales of 5.8 billion won and operating loss of 50 million won.

Humedix (CEO Kang Min jong), an aesthetic subsidiary of Huons Group, reported its first quarter separate sales of 40.1 billion won, operating profit of 11.4 billion won, and net profit of 13.4 billion won, reflecting year on year changes of -2.5%, +7.3%, and +45%, respectively.

Humedix’s performance growth was driven by filler exports, cosmetics, and active pharmaceutical ingredients (API) businesses. In particular, hyaluronic acid (HA) filler showed strong performance.

Since last year, its exports to Brazil continued to grow, and early this year, the company obtained approvals from Thailand on three filler products.Humedix plans to focus on filler exports, leading to steady sales growth. Humedix’s operating profit increased in the first quarter due to improved operating rate of the facility and profitability driven by increased filler exports and API sales.

HuM&C (CEO Kim Jun cheol) a subsidiary specialized in healthcare components, reported its first quarter consolidated sales of 12.5 billion won, operating profit of 512 million won, and net profit of 302 million, with year-on-year changes of +4.4%, -49.6%, and -76.4%, respectively.

HuM&C’s glass business recorded sales of 7.4 billion won, a slight decrease from the previous year, on the other hand, the cosmetics business showed significant growth, recording 5.1 billion won. HuM&C attributed this 77.2% increase to the effects of the business acquisition in the second half of last year.

In the second quarter, HuM&C expects ramp up of its production facility’s operation in Vietnam to strengthen its competitiveness in the glass business.

Huons BioPharma, a subsidiary specializing in botulinum toxin, reported its first quarter sales of 7.2 billion won and operating profit of 1.4 billion won. Overseas sales of toxin products to Thailand and Iraq has increased, but decrease in domestic sales resulted in both sales and operating profit to fall compared to the same period last year.

Huons Meditech recorded sales of 13.3 billion won and an operating loss of 230 million won due to the decrease in exports of medical devices, resulting in a decrease in sales and turning it into a deficit. Food Assemble, a subsidiary specialized in meal kits, recorded 2.4 billion won in sales and reduced its deficit with 517 million won in operating loss.

Huonslab is actively continuing R&D on human hyaluronidase ‘HLB3-002’. It is currently undergoing a pivotal Phase 1 clinical trial in South Korea. Following the completion of the trial, Huonslab plans to apply for approval to MFDS in the second half of this year. Last month, Huonslab announced the result of formulation conversion using ‘HLB3-002’ in a poster presentation at the 2025 Annual Meeting of the American Association for Cancer Research (AACR 2025).

CEO of Huons Global, Song Soo young said “Huons Group will deliver tangible results and secure mid- to long-term growth engines by vowing to step up overseas expansion and R&D investment. We will continue to strengthen compliance and legal management and become a global healthcare leading company that continues to thrive on corporate ethics.”

Huons Global has co CEOs Yoon Sung tae and Song Soo young. Chairman Yoon Sung tae was appointed as Huons Global’s CEO by the board after the 38th annual general meeting of shareholders. Chairman Yoon has been returned to the front lines of management to lead the group’s great leap forward, marking its 60th anniversary this year. His main focus is on expanding its global reach, and securing competitive pipelines through R&D.